Eric Schmidt

Eric Schmidt is recorded as Analyst at Cowen and Company, Analyst at Cantor and Analyst at Cantor Fitzgerald. Earlier roles on record: CFO at Allogene Therapeutics, Inc. (ALLO) until August 2, 2023 and Board Member at Relmada Therapeutics, Inc. (RLMD) until September 5, 2023. Relmada Therapeutics, Inc. reported in an 8-K filed September 6, 2023 that Eric Schmidt resigned as member of the Board of Directors, effective September 5, 2023. Allogene Therapeutics, Inc. reported in an 8-K filed June 14, 2023 that Eric Schmidt resigned as Chief Financial Officer, principal financial officer and principal accounting officer, effective August 2, 2023. The proxy statement of Allogene Therapeutics, Inc. reports total compensation of $5,279,677 for Eric Schmidt in fiscal 2022, including a base salary of $490,000. Disclosed compensation is on record for 5 fiscal years. Eric Schmidt has spoken on 22 earnings calls and 6 other investor events across 9 companies, most recently for Tango Therapeutics, Inc. on October 23, 2026. Those appearances were for Allogene Therapeutics, Inc. (ALLO), Agios Pharmaceuticals, Inc. (AGIO), Biogen Inc. (BIIB), Verastem, Inc. (VSTM), Summit Therapeutics Inc. (SMMT) and 4 other companies. The companies whose calls Eric Schmidt spoke on are classified in the Healthcare sector.